Basic HTML Version
49
october 7-9, 2012 • NEW ORLEANS, LA
P34
CLINICAL RELEVANCE OF THROMBOSPONDIN
RECEPTOR (CD36) EXPRESSION IN EGYPTIAN DE
NOVO ADULT ACUTE MYELOID LEUKEMIA
Dalia Salem
1
, Sherine Abd El-Aziz
1
, Manal Salah-Eldin
2
1
Clinical Pathology Department, Oncology Center, Mansoura
Faculty of Medicine,
2
Medical Oncology Department,
Oncology center, Mansoura Faculty of Medicine
Acute myeloid leukemias (AML) is a heterogeneous group of
disorders which often present with different morphological,
immunophenotypic and cytogenetic patterns. Identification
of these characteristics may be useful for a better prognostic
evaluation and for a more appropriate therapeutic approach.
CD36 is a transmembrane, highly glycosylated, glycoprotein
commonly expressed on blasts in acute monocytic leukemia,
megakaryoblastic leukemia, and erythroleukemia. In
this study, we evaluated CD36 surface expression in 97
newly diagnosed Egyptian AML patients, and results were
correlated with morphology, immunophenotype, cytogenetic
pattern and clinical outcome. CD36 antigen was recorded
in 48 out of 97 cases (49.5%) and particularly in those with
M5 and M6 FAB subtypes. Moreover, CD36 expression
was significantly associated with expression of CD11b (p
= 0.001) and CD14 (p = 0.0001), unfavorable cytogenetic
abnormalities (p = 0.001), shorter overall survival (p >
0.0001) and leukemia free survival (p = 0.03). On the
basis of the study results, it can be concluded that CD36
expression in AML patients may identify a subgroup with
poor prognosis, and thus may be a valuable adjunct to be
added to the current prognostic factors.
P35
THE EFFECT OF DIFFERENT ANTICOAGULANTS ON
SPECIMEN STABILITY AND LEUKOCYTE SUBSETS
Margo I Santiago, Maryalice Stetler-Stevenson, Constance
Yuan, Prashant Rameshq
NCI
Introduction:
A single cell suspension is required for
flow cytometry (FC). For this reason clotting must be
prevented in blood or bone marrow via anticoagulant. Cells
must also be viable or non-specific binding of antibodies
will occur. Ethylene-diaminetetraacetic acid (EDTA) and
sodium heparin are commonly used anticoagulants for
both blood and bone marrow. Debate still remains about
which anticoagulants produce the most viable results when
processed immediately, and those processed in 24 hours
after collection. In this study we compare FC analysis of split
EDTA and sodium heparin anticoagulated blood processed
immediately and 24 hours after collection.
Methods:
Both
EDTA and sodium heparin anticoagulated blood were
collected from normal donors at the same time point. Half
of each was processed immediately and the remaining half
held at room temperature overnight. NH4Cl red cell lysis
was performed and both viability analyzed (using 7AAD
staining) and T, B and NK cell subsets quantified by FC.
Results:
Although viability was comparable when staining
was performed same day, there was a significant decrease
in viability in EDTA compared to heparin anti-coagulated
blood at 24 hours.
Conclusion:
Heparin anti-coagulant is
preferable to EDTA in specimens not being immediately
processed for FC
POSTER ABSTRACTS